Industry Abstract Previews - ACR2020 Save

Jack Cush, MD

Nov 06, 2020 12:33 am

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our selection of their best studies for you to review and evaluate as part of your to-do list. In the least, you should be familiar with the names and objectives of some of these studies as they will be discussed and mentioned throughout the meeting.

Novartis

Novartis featured several abstracts evaluating the efficacy, imaging outcomes, US measured synovitis and insights from machine learning.

Sponsor	Abstract #	Featured Abstract
Novartis	1361	Secukinumab significantly decreased joint synovitis measured by power Doppler ultrasonography in biologic-naïve patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled Phase III study.
Novartis	364	Subcutaneous secukinumab 150 mg provides sustained relief in total and nocturnal back pain, morning stiffness, fatigue, and low disease activity in patients with active ankylosing spondylitis: End-of-study (5-year) data from the MEASURE 2 trial
Novartis	505	Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: Results from the MAXIMISE trial
Novartis	2017	Machine learning identifies an association between pre-existing radiographic damage and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis

Janssen

Janssen announced for it's presentations at the ACR 2020 meeting, featuring new data on Remicade, Simponi, Simponi Aria, Stelara, and Tremfya (guselkumab). Overall, Janssen has 35 abstracts on the programe, with clinical trial data on psoriatic arthritis (PsA), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). There were 16 abstracts on Tremfya (guselkumab) in adults with active PsA, including 52-week safety and efficacy data and spinal outcomes. Below are highlighted studies.

Sponsor	Abstract #	Featured Abstract
Janssen	506	DISCOVER 2 Trial - Efficacy and safety of TREMFYA through week 52 in biologic-naïve patients with active psoriatic arthritis. This oral presentation is scheduled for Friday, Nov. 6 from 3:30-3:40 p.m.
Janssen	2025	DISCOVER 1 and 2; Efficacy of TREMFYA on axial-related endpoints in patients with active PsA who have imaging-confirmed sacroiliitis at 52 weeks. This oral presentation is scheduled for Monday, Nov. 9 from 11:20-11:30 a.m.
Janssen	349	Pooled Safety Results of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year. Poster presented on Friday, Nov. 6, 9-11 a.m.
Janssen	1826	Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus (SLE): 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study. Poster presented Monday, Nov. 9, 9-11 a.m.

Bristol Myers Squibb (BMS)

BMS announced that 26 company-sponsored and collaborative studies will be presented at ACR Convergence between November 5-9, 2020. Research was focused on 3 therapeutic interventions – Orencia, Deucravacitinib (BMS-986165; a TYK2 inhibitor) and Iberdomide (a high-affinity, cereblon ligand). Here are highlighted studies:

Sponsor	Abstract #	Featured Abstract
BMS	L03	Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results From a Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. Poster to be presented Monday, November 9, 9:00 – 11:00 a.m. EST
BMS	801	The Comparative Effectiveness of Abatacept Versus TNF Inhibitors in Patients who are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study. Poster Session B on Saturday, November 7, 9:00 – 11:00 a.m. EST
BMS	824	The Comparative Effectiveness of Abatacept Versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a U.S. National Observational Study. Poster Session B on Saturday, November 7, 9:00 – 11:00 a.m. EST
BMS	987	Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study. An oral presentation on Saturday, November 7, 3:20 – 3:30 p.m. EST

AstraZeneca

AstraZeneca announced results from new analysis of its Phase III TULIP trials, evaluating anifrolumab in patients with systemic lupus erythematosus (SLE).

Sponsor	Abstract #	Featured Abstract
AstraZeneca	1827	Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials [Poster]

Eli Lilly & Co.

Lilly announced several new trials will be presented at ACR 2020 on Olumiant (baricitinib) including long-term studies and real-world evidence (RWE) on safety and efficacy.

Sponsor	Abstract #	Featured Abstract
Lilly	224	Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis by Alvin Wells et al
Lilly	1235	Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND will be presented by Désirée van der Heijde, et al.
Lilly	203	Safety of Baricitinib in Patients with Rheumatoid Arthritis: Interim Report from All-Case Post‑Marketing Study in Clinical Use will be presented by Tatsuya Atsumi, et al
Lilly	202	Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis. An integrated safety analysis of pooled data from nine clinical trials of baricitinib; presented by Kevin Winthrop, et al.

Horizon Therapeutics

Horizon announced several new trials studying the efficacy and safety of Krystexxa (pegloticase) in refractory gout and whether coadministration of DMARDs improves outcomes.

Sponsor	Abstract #	Featured Abstract
Horizon	952	Reducing Immunogenicity of Pegloticase [RECIPE] with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout —A Phase 2 Double Blind Randomized Controlled Trial. An oral presentation on Nov. 7 at 5:20 p.m. ET
Horizon	677	(A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
Horizon	655	Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study

Genentech

Genentech announced results from the Phase II NOBILITY study will be presented during 2020 ACR Convergence meeting. This trial studied Gazyva (obinutuzumab) in patients with proliferative lupus nephritis.

Sponsor	Abstract #	Featured Abstract
Genentech	988	NOBILITY study - Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis. An Oral presentation on Saturday Nov. 7^th, 3-350 pm EST